Safety and tolerability

The safety and tolerability of BIKTARVY®▼ (bictegravir / emtricitabine / tenofovir alafenamide) is consistent between treatment-naïve and virologically suppressed adults.1 The most frequently reported adverse reactions from phase III trials involving both cohorts is summarised below.